A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

By B. Sangro, C. Gómez-Martín, M. L. de la Mata, M. Iñarrairaegui, E. Garralda, P. Barrera, J. Riezu-Boj, E. Larrea, C. Alfaro, P. Sarobe and 4 more. Journal of Hepatology, 2013

933 citations recorded by the source corpus.

Subfields: Genetics, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/676ca90c08e7a1a7f4e332c9406f5e83d89185a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. M. Kudo
2. A. Cheng
3. T. Greten

In Oncology

1. M. Hughes

Citations in the corpus

• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “48 months in 21 HCV-related HCC patients who had failed at least one line of systemic therapy [604].”
• Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma (2016, positive): “Tremelimumab is well tolerated when administered as a single agent to patients with HCC [13].”